The Lunenfeld-Tanenbaum Research Institute (LTRI) is a world-class academic health sciences centre and one of the country’s top research institutes.
Support from the Mount Sinai Classic is critical to advancing research at Sinai Health’s LTRI, allowing our scientists to explore the uncharted corners of science and push boundaries that result in groundbreaking discoveries. Below are some of the key areas where LTRI researchers are paving the way for the next discovery.
The LTRI ranks #1 in the world for high-impact diabetes research among best-in-class hospital peers and is home to some of the top diabetes researchers in the world.
Research at the LTRI has revolutionized our approach to understanding how memories are formed, retained and lost. This work has contributed to a medication that temporarily slows down the progression of Alzheimer’s disease.
More than 40 per cent of the research done at the LTRI is cancer-related, and it ranks among the top three centres for sarcoma research in the world.
The LTRI has one of the world’s largest concentrations of scientists studying women’s and infants’ health and is known for its world-renowned research programs in neonatal medicine, placental health, and maternal/fetal medicine.
The Centre of Excellence in Precision Medicine for Arthritis and Autoimmune Disease is harnessing emerging technology and research in precision medicine to provide more personalized care for our patients.
Research at the Bridgepoint Collaboratory, part of the LTRI, is focused on quality and health system performance through the eyes of complex patients and their caregivers, with the goal of creating approaches to care that is more person-centred.
At the LTRI, they are uncovering better ways to diagnose and treat the disease including developing the first ultra high throughput SARS-CoV-2 test with the goal to run 10,000 tests daily.